Cargando…

A Randomized Trial of a New Triple Drug Treatment for Lymphatic Filariasis

BACKGROUND: The recommended drug regimen for elimination of lymphatic filariasis outside sub-Saharan Africa is single dose of diethylcarbamazine (DEC) plus albendazole (ALB). Multiple annual treatments are required for elimination since this regimen does not sustainably reduce blood microfilaria (Mf...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Christopher L., Suamani, James, Sanuku, Nelly, Cheng, Yao-Chieh, Satofan, Samson, Mancuso, Brooke, Robinson, Leanne J., Siba, Peter M., Weil, Gary J., Kazura, James W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194477/ https://www.ncbi.nlm.nih.gov/pubmed/30403937 http://dx.doi.org/10.1056/NEJMoa1706854

Ejemplares similares

Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis
por: Andersen, Britt J, et al.
Publicado: (2018)

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
por: Weil, Gary J, et al.
Publicado: (2020)

Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys
por: Berg Soto, Alvaro, et al.
Publicado: (2018)

Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
por: Tisch, Daniel J., et al.
Publicado: (2011)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

Sequential Modelling of the Effects of Mass Drug Treatments on Anopheline-Mediated Lymphatic Filariasis Infection in Papua New Guinea
por: Singh, Brajendra K., et al.
Publicado: (2013)

Correction: Sequential Modelling of the Effects of Mass Drug Treatments on Anopheline-Mediated Lymphatic Filariasis Infection in Papua New Guinea
por: Singh, Brajendra K., et al.
Publicado: (2014)

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis
por: Pantelias, Anastasia, et al.
Publicado: (2022)

Understanding heterogeneities in mosquito-bite exposure and infection distributions for the elimination of lymphatic filariasis
por: Irvine, Michael A., et al.
Publicado: (2018)

A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
por: Krentel, Alison, et al.
Publicado: (2021)

Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa
por: Graves, Patricia M., et al.
Publicado: (2021)

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
por: Weil, Gary J., et al.
Publicado: (2019)

Single dose triple drug therapy completely suppresses Wuchereria bancrofti microfilaremia for 5 years
por: King, Christopher L., et al.
Publicado: (2020)

Global Eradication of Lymphatic Filariasis: The Value of Chronic Disease Control in Parasite Elimination Programmes
por: Michael, Edwin, et al.
Publicado: (2008)

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria
por: Eneanya, Obiora A, et al.
Publicado: (2023)

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis
por: Weil, Gary J., et al.
Publicado: (2022)

A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis
por: Krentel, Alison, et al.
Publicado: (2013)

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
por: Tavul, Livingstone, et al.
Publicado: (2022)

The Impact of Repeated Rounds of Mass Drug Administration with Diethylcarbamazine Plus Albendazole on Bancroftian Filariasis in Papua New Guinea
por: Weil, Gary J., et al.
Publicado: (2008)

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach
por: Goss, Charles W., et al.
Publicado: (2019)

Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis
por: Gambhir, Manoj, et al.
Publicado: (2010)

Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
por: Stolk, Wilma A., et al.
Publicado: (2013)

The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
por: Rainima-Qaniuci, Merelesita, et al.
Publicado: (2022)

Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
por: Andersen, Britt J., et al.
Publicado: (2019)

Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo
por: Chesnais, Cédric B., et al.
Publicado: (2019)

MDA—Lymphatic Filariasis
por: Ichimori, Kazuyo
Publicado: (2014)

Urban lymphatic filariasis
por: Simonsen, Paul E., et al.
Publicado: (2012)

A case study of risk factors for lymphatic filariasis in the Republic of Congo
por: Chesnais, Cédric B, et al.
Publicado: (2014)

Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned
por: Tripathi, Bhupendra, et al.
Publicado: (2022)

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
por: Budge, Philip J., et al.
Publicado: (2018)

Portable infrared imaging for longitudinal limb volume monitoring in patients with lymphatic filariasis
por: Zhou, Celia, et al.
Publicado: (2019)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Endpoints for Lymphatic Filariasis Programs
por: Grady, Caroline A., et al.
Publicado: (2007)

Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis
por: Jacobson, Julie
Publicado: (2022)

Mapping of lymphatic filariasis in Nepal
por: Sherchand, Jeevan B, et al.
Publicado: (2003)

Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia
por: Supali, Taniawati, et al.
Publicado: (2019)

IgG(4) antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis
por: Greene, Sarah E., et al.
Publicado: (2023)

Evaluating the Evidence for Lymphatic Filariasis Elimination
por: Davis, Emma L., et al.
Publicado: (2019)

Mapping the Geographical Distribution of Lymphatic Filariasis in Zambia
por: Mwase, Enala T., et al.
Publicado: (2014)

Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis – a multicenter trial
por: Lammie, Patrick J, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_gh5d51of54nnomgfjf6eaq3kmg